SANTA ANA, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) ('NKGen” or the 'Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced upcoming poster presentations on a final report of a Phase 1 dose escalation study and on a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in subjects with Alzheimer's disease, at the 17th Annual Clinical Trials on Alzheimer's Disease Conference ('CTAD”) to be held in Madrid, Spain from October 29 - November 1, 2024.
Presentation Details: